We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+23.45%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
+$331M
Cap. Flow
+$76.5M
Cap. Flow %
4.56%
Top 10 Hldgs %
63.28%
Holding
89
New
21
Increased
18
Reduced
12
Closed
21

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.9M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$12.3M
4
AMGN icon
Amgen
AMGN
+$12.2M
5
MGNX icon
MacroGenics
MGNX
+$10.6M

Top Sells

Rank Stock Value
1
NXTC icon
NextCure
NXTC
+$23.5M
2
MRK icon
Merck
MRK
+$15.8M
3
LLY icon
Eli Lilly
LLY
+$15.8M
4
INSM icon
Insmed
INSM
+$11.2M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$7.46M

Sector Composition

Rank Sector Weight
1 Healthcare 91.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$309M 18.37%
3,100,560
– –
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$198M 11.81%
1,952,441
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$16.7B
$185M 11.02%
1,109,874
– –
YMAB
4
DELISTED
Y-mAbs Therapeutics
YMAB
$109M 6.47%
2,194,278
– –
UTHR icon
5
United Therapeutics
UTHR
$26.3B
$52.8M 3.14%
347,901
+26,942
+8% +$3.54M
CMPI
6
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$52.6M 3.13%
3,606,707
– –
AZN icon
7
AstraZeneca
AZN
$263B
$42.1M 2.51%
+421,300
New +$44.6M
INZY
8
DELISTED
Inozyme Pharma
INZY
$41.9M 2.49%
2,028,308
– –
AMGN icon
9
Amgen
AMGN
$203B
$37.9M 2.25%
164,663
+53,044
+48% +$12.2M
JAZZ icon
10
Jazz Pharmaceuticals
JAZZ
$15.9B
$35.1M 2.09%
212,911
+82,643
+63% +$12.3M
XLV icon
11
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
$34M 2.03%
+300,000
New +$32.7M
GRTX
12
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$31.5M 1.88%
3,083,712
– –
ABBV icon
13
AbbVie
ABBV
$458B
$31.5M 1.87%
293,596
-47,744
-14% -$4.59M
AKUS
14
DELISTED
Akouos Inc
AKUS
$30M 1.79%
1,515,074
+1
+0% +$19
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$27M 1.61%
848,162
+344,607
+68% +$9.06M
IWM icon
16
PUT
iShares Russell 2000 ETF
IWM
$80.9B
$25.5M 1.52%
+130,000
New +$22.7M
NCNA
17
NuCana
NCNA
$5.37M
$25.1M 1.5%
1,120
– –
MRUS
18
DELISTED
Merus
MRUS
$23M 1.37%
1,311,039
– –
PTCT icon
19
PTC Therapeutics
PTCT
$6.37B
$19.3M 1.15%
316,478
-88,674
-22% -$5.23M
RETA
20
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$18.4M 1.1%
148,937
+80,322
+117% +$10.6M
LONA
21
LeonaBio Inc
LONA
$69.4M
$17.4M 1.04%
50,917
– –
OTIC
22
DELISTED
Otonomy, Inc.
OTIC
$17M 1.01%
2,620,668
+509,072
+24% +$2.31M
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$15.6M 0.93%
+213,390
New +$15.9M
BMRN icon
24
BioMarin Pharmaceuticals
BMRN
$11.5B
$14.4M 0.86%
164,545
-94,108
-36% -$7.46M
ACRS icon
25
Aclaris Therapeutics
ACRS
$730M
$12.4M 0.74%
1,911,573
– –
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2020 Portfolio in Review

As of Q4 2020, Sofinnova Investments held 89 positions worth $1.68B, up 25% from $1.35B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sofinnova Investments deployed $76.5M of net new capital in Q4 2020, opening 21 new positions and adding to 18 existing holdings. Its largest new stake was AstraZeneca: 421,300 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 93% a quarter earlier.

On the sell side, the largest reduction was Eli Lilly, an estimated $15.8M trimmed.

  • Sofinnova Investments's largest Q4 2020 buy was AstraZeneca: 421,300 shares worth $42.1M.
  • Sofinnova Investments added most to Jazz Pharmaceuticals in Q4 2020, an estimated $12.3M increase.
  • Sofinnova Investments's biggest Q4 2020 reduction was Eli Lilly, cutting an estimated $15.8M.
  • Sofinnova Investments fully exited NextCure in Q4 2020, selling an estimated $23.5M.
  • Sofinnova Investments's ten largest holdings make up 63% of its $1.68B portfolio in Q4 2020.
  • Sofinnova Investments opened 21 new positions and closed 21 in Q4 2020.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.68B.

Based on Sofinnova Investments's 13F filing for Q4 2020, filed 16 Feb 2021.